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Drug induced complication are becoming increasingly common in CF. In this review we discuss some of the key issues relating to drug side in
an ageing population of patients with CF. Strategies to reduce drug complications are also discussed.
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Cystic fibrosis (CF) is a multisystem disease characterized
by chronic endobronchial infection and progressive obstructive
lung disease. While there is still no cure, recent advances have⁎ Corresponding author. Tel.: +44 1132067179.
E-mail address: daniel.peckham@btinternet.com (D. Peckham).
1569-1993/$ -see front matter © 2013 European Cystic Fibrosis Society. Published
http://dx.doi.org/10.1016/j.jcf.2013.04.014significantly increased average life expectancy with patients
born at the start of the 21st century having an estimated median
survival of 50 years. These dramatic changes in survival have
occurred over decades and result from a proactivemultidisciplinary
approach to treatment combined with early antibiotic therapy.
Treatment is now aimed at protecting specific organ damage,
reducing early bacterial colonisation, preventing pulmonary
exacerbations and inhibiting airway inflammation so that lung
function can be maintained.by Elsevier B.V. All rights reserved.
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medication which is onerous and leads to poor adherence.
The problem is compounded by the fact that individuals can
remain relatively asymptomatic despite significant decline in
organ function. Symptoms are often a poor marker of disease
severity, and other factors such as lung function, Pseudomonas
aeruginosa status, liver function, exercise tolerance, CF related
diabetes (CFRD) and chest radiology need to be monitored. It is
vital that patients appreciate the real benefits of treatments which
they perceive as having no immediate impact on their health.
Prevention of disease progression remains key to further
improvements in outcome.
With increased patient survival and the advent of a generation
of older patients with CF, health care professionals are faced with
new complications such as diabetic vasculopathies, cardiovascu-
lar disease and renal failure. This will be particularly relevant to
those living into old age and those who undergo transplantation.
Clinicians often feel powerless to halt the progressive nature
of chronic disease and this can result in overprescribing of
medication which is often not evidence based and can result in
significant and severe adverse events. Optimising treatment
requires the potential benefits of a specific treatment to be
balanced against long term adverse effects and quality of life
rather than increasing medication in the hope that improve-
ments will occur.
In this short review we discuss some of the key issues
relating to drug side effects in an ageing population of patients
with CF and challenge the logic behind some of the standard
drug regimens in use today.
2. Mechanisms, clinical manifestation and impact
2.1. Pancreatic enzymes
The introduction of acid-resistant pH sensitive microsphere
pancreatic enzymes resulted in a significant improvement inFig. 1. Barium enema and histology of the colon showing foverall health and nutritional status. Unfortunately between
October 1993 and November 1994, 13 children with CF on high
strength pancreatic enzymes developed large bowel strictures
relating to a combination of newer preparations of enzymes and
high dosing schedules. The first cases of fibrosing colonopathy
(Fig. 1) were reported by Smyth et al. who described four cases of
ascending colon stricture with histopathological changes of post-
ischaemic ulceration repair and mucosal and submucosal fibrosis,
pathological features which had not been previously known to
occur in CF [1]. The only common change in the management of
these children was a switch from conventional enteric-coated
pancreatic enzymes to high-strength products 12–15 months
before presentation. This was a serious and avoidable complica-
tion highlighting the importance of drug surveillance. Initially it
was believed that fibrosing colonopathy was due to high doses of
pancreatic enzymes. However, Creon 25,000 was never implicat-
ed and it is now believed that it results from the use of methacrylic
acid copolymer in the enteric coating. This coating was also
present in some low strength enzymes and in other drugs, such as
mesalazine, where similar complications have been reported [2].
It is now recommended that patients should usually have a
maximum enzyme dose of 10,000 IU lipase per kg day and
certain preparations such as Pancrease HL, Nutrizyme 22 and
Panzytrat 25,000 should be avoided in children aged 15 years or
less [3].
2.2. Early treatment of abnormal glucose metabolism
The prevalence of cystic fibrosis related diabetes (CFRD)
increases with age and is now one of the most common non-
respiratory complications. There remains much controversy about
both the diagnosis of CFRD and the early detection of abnormal
glucose metabolism. Early diagnosis and intervention are key
as CFRD has a negative impact on lung function, weight and
survival. Complications such as retinopathy, nephropathy,
microalbuminuria and neuropathy are commonly seen [4].ibrosing colonopathy (The History of Cystic Fibrosis).
Fig. 2. MRI scan showing vertebral fractures (L3, L4, L5) in a patient with
osteoporosis.
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contribute directly to clinical decline and that continuous glucose
monitoring shows pathological glucose excursion in both patients
with impaired and normal glucose tolerance. In response to these
findings there is a growing trend to treat patients with insulin in
the early pre-diabetic stages of disease [5,6]. Clinical trials are
needed to clarify the risk benefit of such a move as early
intervention can result in early stigmatisation, increased burden
of treatment and has the potential for inducing hypoglycaemia
and affecting cognition, an area which our group is presently
investigating [7]. Conversely there is a need to improve diabetic
control and reduce the risk of complications such as chronic renal
failure.
There is a lack of evidence to support the routine use of oral
hypoglycaemic agents in the treatment of CFRD and insulin is the
only recommended treatment. [8–10]. Despite growing evidence
pointing to an association between early hyperglycaemia and a
negative clinical outcome, it is our view that there is insufficient
data to support the routine use of early insulin therapy in the pre
diabetic stage of CF. We do however use insulin in selected cases
where weight loss remains a problem and subcutaneous continuous
glucosemonitoring showsmild elevation in glucose. An alternative
might be to assess the “CF diet”, based on a high calorie intake
which may include large quantities of refined sugars. Perhaps the
time has come to revise dietary guidelines in recognition that most
patients with CF will eventually develop insulin deficiency with or
without CFRD.
2.3. Corticosteroids
Corticosteroids can induce hyperglycaemia and insulin resis-
tance in patients with andwithout CFRD. Even low dose regimens
in healthy individuals can impair glucose tolerance and interfere
with the metabolic actions of insulin on liver and adipose tissue
[11]. Despite the adverse effects associated with steroids, they
remain an important part of the arsenal used in the treatment of
conditions such as atopy, airway inflammation, gout, arthritis, drug
allergy, prophylaxis for bisphosphonate infusions and allergic
bronchopulmonary aspergillosis (ABPA). Oral steroids are usually
prescribed for short periods of time to avoid side effects, although
some patients require frequent and prolonged courses. As well as
impacting on the control of CFRD, steroids are responsible for a
significant number of adverse effects including recurrent oral and
genital candidiasis, fragile skin, behavioural changes, peptic
ulceration, growth retardation, cataracts and osteoporosis (Fig. 2)
[12,13]. New regimens for the treatment of ABPA may help
reduce steroid induced complications although further clinical
trials are needed to ensure both their safety and their efficacy. One
option could be to use monthly pulses of high-dose intravenous
methylprednisolone which has been reported to induce fewer side
effects [14]. Alternatively monoclonal anti-IgE antibody therapy
(omalizumab) could be considered for the management of ABPA
in individuals who have become steroid dependent and/or require
frequent prolonged courses of treatment [15,16]. Most available
data is based on case reports and randomised controlled trials are
needed to assess the effectiveness of such therapies before they
become routine. The urgent quest to identify alternatives to steroidsneeds to be considered in the context of ensuring that any benefit is
not negated by unforeseen complications.
Bisphosphonates are potent inhibitors of osteoclastic bone
resorption and are effective in the prevention of CF and steroid
induced osteoporosis [17,18]. Complications which are com-
monly associated with intravenous preparations include severe
bone pain, flu-like symptoms, muscle aches and gastrointestinal
symptoms. Pre-dosing with oral steroids can significantly reduce
the prevalence and severity of non-gastrointestinal symptoms. It
is key to ensure good dental hygiene as there is a potential risk of
bisphosphonate associated osteonecrosis of the jaw.
Over 40% of patients with CF are prescribed inhaled
corticosteroids (ICS) based on either the presence of reversible
airway bronchoconstriction or on the rationale that treatment may
reduce airway inflammation and decline in lung function [19]. In
practice many patients are prescribed treatment for symptoms of
wheezewhich is also common in acute bacterial infection and often
resolves with intravenous antibiotics. Because of the difficulty of
measuring the clinical benefits of ICS objectively “treatment may
be continued unnecessarily”. There are several studies demonstrat-
ing that ICS in children with CF is associated with a slower decline
in lung function [19]. In contrast ICS therapy has been reported to
be associated with significant complications including reduced
growth, adrenal suppression and a potential increase in the risk of
pulmonary exacerbations [12,19–21]. Reassuringly, withdrawal of
ICS in non-atopic individuals does not appear to be associated with
an earlier onset of acute pulmonary exacerbations [22].While these
results cannot predict the long term efficacy of treatment, they
provide supporting evidence that a trial of ICS withdrawal may be
appropriate and safe. Patients on concomitant itraconazole are
particularly at risk of developing Cushing's syndrome and adrenal
insufficiency due to the drugs inhibition of cytochrome P450
enzymes [23,24].
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Seminal work by Crozier radically changed the nutritional
status of patients by demonstrating the importance of a normal
or high fat intake in combination with pancreatic enzymes
[25]. This was contrasted with the prevailing clinical view that
advocated fat-restriction. Today over 10% of patients with CF
are classified as overweight or obese [26]. Although these
patients often havemutations associated with milder CF phenotype
and may be pancreatic sufficient they do display higher levels of
LDL cholesterol and fasting insulin levels compared with normal
or underweight patients with CF [27]. We have recently
demonstrated similarly abnormal lipid profiles in patients with
and without CFRD and post solid organ transplant (Fig. 3). In
addition to diet, drugs such as corticosteroids, oral contraception
and anti-rejection medication can adversely affect lipid profiles.
Poor nutrition in patients with CF is associated with poor
clinical outcome and early intervention remains essential for
normal growth and development to be achieved. However, the
impact of nasogastric and enterostomy feeding on adipose tissue
deposition needs further investigation. Being heavier does not
equate to being fitter and feeding regimens may inadvertently
affect the pathophysiology of both CFRD and cardiovascular
disease by altering the deposition of adipose tissue. Deposition in
the viscera is associated with a higher cardiovascular (CVD) risk
in contrast to subcutaneous deposition which may act as a buffer
for excess dietary energy [28].
Studies have already shown increased arterial stiffness
in patients with CF, an indicator of premature ageing and
perhaps a predicator of things to come [29]. Inflammation
is another key factor which may predispose patients with CF to
developing atherosclerosis later in life [30,31]. Markers of
inflammation, such as high sensitivity CRP, strongly predict
the development of cardiovascular disease [32]. This hypoth-
esis is supported by increased cardiovascular complications in
patient cohorts with chronic inflammation such as rheumatoidFig. 3. Age and cholesterol/HDL ratio in 410 paarthritis [31]. Although there are few cases of ischaemic heart
disease in the literature, CF itself, as well as CFRD, could be an
independent risk factor for the future development of CVD
especially in the light of increased longevity and in patients
undergoing transplantation (Fig. 4).2.4.1. Intravenous antibiotics
Intravenous antibiotics are used to treat acute pulmonary
exacerbations, as part of eradication therapy or to help control
chronic infection. At present prompt and appropriate management
of pulmonary exacerbations is the cornerstone of effective CF
management. There are no high quality randomised controlled
studies supporting the use of routine intravenous antibiotics in
patient with CF. Pedersen et al. showed an increase from a five
year survival of 54% to a 10 year survival of 90% from the onset
of chronic P. aeruginosa infection with three monthly elective
intravenous antibiotics irrespective of their clinical condition [33].
Since this early study treatment has progressed with improved
nutrition, the introduction of dornase alpha and nebulised
antibiotics. Unfortunately the only randomised controlled
trial seeking to address this issue was underpowered and no
differences were observed between those receiving elective
versus symptomatic treatment [34].2.4.2. Choice of antibiotic for exacerbation
Most centres continue to use combination intravenous antibi-
otics for exacerbations which include the addition of either an
aminoglycoside or colistin with a beta lactam antibiotic. Both
aminoglycosides and colistin are nephrotoxic. Risk of such
complications is dependent on dose, duration and frequency of
administration [35,36]. The potential benefits of combination
therapy include synergy and reduction of bacterial resistance.
However, the evidence for such strategies is inconclusive and
the practice has substantial potential for causing long term
harm especially as patients are living longer and the risk oftients attending the Leeds Regional CF unit.
Fig. 4. Cardiac allograft vasculopathy in a 17 year old patient post-heart lung
transplant.
551D. Peckham, P. Whitaker / Journal of Cystic Fibrosis 12 (2013) 547–558serious adverse events from a lifetime of frequent antibiotic
treatment is significantly increased [37,38].
Whilst combination intravenous therapy is standard practice
there is little evidence to support its role over monotherapy. This
reflects the lack of high quality randomised controlled trials [37].
Indeed monotherapy has some attractive features such as reduced
toxicity and cost. An alternative regimen is to combine an inhaled
and intravenous antibiotic for the treatment of exacerbations to
reduce potential side effects and directly target P. aeruginosa in the
endobronchial space. This has the added advantage of achieving a
higher concentration of the drug within the airways. Further
randomised controlled trials are needed to assess the relative
benefit of such treatment especially in younger patients with more
limited respiratory disease.
2.4.3. Duration and dose of treatment
Reduced aminoglycoside toxicity can be achieved by using
tobramycin rather than gentamicin on a once daily regimen [39].
Other potential solutions include reducing the length of treatment
and adjusting and monitoring drug doses more effectively [40].
Standard treatment is for 14 days although there are no randomised
controlled trials comparing treatment duration. Shorter courses are
advantageous in terms of reduced toxicity, hypersensitivity and
cost. Collaco et al. demonstrated that most lung function recovery
was reached within a week of treatment and that a plateau was
reached at 8–10 days [41]. It is not known whether reducing
treatment durationwould lead to a shorter time to next exacerbation
or a more accelerated decline in lung function. It is clear, however,
that pulmonary exacerbations result in progressive irrecoverable
loss in lung function with a quarter of patients failing to recover
their lung function within three months of an exacerbation [42].In addition to duration of treatment, patients often receive
higher doses than the general population relating to increased
volume of distribution and more rapid drug elimination.
Treatment doses are also aimed at ensuring that adequate
levels penetrate the infected lung. This can be a problem as
some drugs, such as the aminoglycosides, have very poor
penetration into bronchial secretions [43] whilst endobronchial
beta-lactam levels are less than 15% of plasma levels [44].
2.4.4. Nebulised antibiotics
The use of nebulised antibiotics is critical in ensuring clinical
stability in patients with CF. Appropriate use of nebulised
antibiotics significantly reduces the risk of pulmonary exacerba-
tion and cause fewer side effects than intravenous therapy [45].
Historically, a continuous regimen has been used with colistin
and intermittent use with tobramycin and aztreonam. Benefits of
intermittent therapy include reduced treatment burden and toxicity
although some patients report that they feel worse during their
month off treatment. Whilst tobramycin is generally well tolerated
it can be associated with tinnitus and nephrotoxicity [46,47]. Other
potential benefits of intermittent therapy include reduced bacterial
resistance and better patient adherence. Unfortunately studies to
date are inconclusive; no significant differences were seen in the
only head-to-head comparison of intermittent tobramycin (300 mg
twice daily) versus tobramycin 80 mg twice daily given continu-
ously [48]. However, the results are difficult to compare given the
different doses.
Several novel antipseudomonal antibiotic preparations are in
development including nebulised amikacin, levofloxacin, cipro-
floxacin, and fosfomycin/tobramycin as well as dry powder
preparations of tobramycin and colistin. It is intriguing to note
that the introduction of new nebulised antibiotics in patients who
have been on alternative agents is often associated with additional
benefit. Examples include the introduction of nebulised tobramycin
and aztreonam in patients previously exposed to colistin and
tobramycin respectively [49,50].We hypothesise that one potential
approach could be to rotate the various groups of nebulised
antibiotics as part of a drug holiday thereby reducing potential
bacterial resistance and increasing effectiveness of therapy.
Clinical trials would be needed to be undertaken to address this
hypothesis before such a regimen could be considered. Dry
powder inhalers are convenient and effective and favoured
over nebulised drugs by many patients for their ease and speed
of administration [51].
2.4.5. Aminoglycosides and ototoxicity
Aminoglycosides are commonly used in combination with
other agents in the treatment of pulmonary exacerbations.
Unfortunately aminoglycosides are associated with the devel-
opment of auditory and vestibular toxicity and in Leeds we are
seeing a growing number of patients with significant hearing
loss necessitating hearing aids (Fig. 5). Studies suggest that
risk is not simply related to exposure but is also linked to
mitochondrial mutations such as m.1555A N G [52,53]. However,
most patients develop toxicity following exposure to frequent and
or high doses of aminoglycosides. This is likely to get worse as
life expectancy increases. One agent used in the treatment
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amikacin. This drug appears to have a predilection to causing
auditory and vestibular toxicity although this may be due to the
intensity and frequency of treatment [54,55]. Routine monitoring
of renal clearance, through levels and regular (high tone) hearing
tests should be undertaken. In patient who develop complica-
tions, alternative antibiotics should be prescribed.
2.4.6. Drug hypersensitivity
Hypersensitivity reactions to antibiotics are up to three times
more common in patients with CF compared with the general
population [56–58]. Whilst hypersensitivity reactions to other
classes of drugs occur the majority of reactions encountered are
attributed to beta-lactams (Fig. 6). Drug reactions to antibiotics
make it increasingly difficult to treat infective exacerbations of
CF effectively. It has a major impact within the hospital both due
to prolonged hospital stays and the use of expensive alternative
antibiotics. A number of patients have been turned down for lung
transplantation as a direct result of multiple drug allergies.
Our experience in Leeds is comparable with the published data
[59,60]. A retrospective review in 2011 identified 302 beta-lactam
reactions in 375 patients (Unpublished data). Only 6% were
immediate reactions due to either anaphylaxis or urticaria; severalFig. 5. Hearing aid in a patient who developed deafness following repeated
intravenous aminoglycoside therapy.of these were skin prick positive suggesting an IgE mediated
process. The vast majority presented as non-immediate rashes,
fixed drug eruptions, arthralgia, and drug fever. Ceftazidime was
the commonest culprit antibiotic followed by piperacillin. Many
patients had more than one beta-lactam hypersensitivity reaction
with 20% having had a single beta-lactam reaction and 30% having
multiple beta-lactam reactions. Not unexpectedly we found that
sicker patients who require more treatment have an increased
risk of developing hypersensitivity reactions. Significant risk
factors in review included female gender, intravenous antibi-
otic use, P. aeruginosa status, CF related arthritis, higher IgG3
levels, and lower IgG4 levels. There was a non-significant
trend towards lower FEV1 and lower bone density.
Antibiotics are delivered intravenously at high doses, for
prolonged periods, and on a repeated basis. It is likely that these
alone are sufficient to drive sensitization and hence sensitivity.
The intravenous route appears particularly immunogenic and
very little hypersensitivity is seen with oral or inhaled therapy.
We have recently published a case series the results of which
suggest that even with proven hypersensitivity to intravenous
aztreonam, patients were able to tolerate inhaled aztreonam
without adverse effects [59]. This is similar to our experiences
with colistin; many patients tolerate the nebulized form when
they have adverse effects with the drug intravenously.
The dose and duration of antibiotic therapy is also important.
The binding of piperacillin to albumin is concentration and
time-dependent; patients with CF usually receive 14 days of
intravenous treatment. In-vitro 13 out of 59 lysine residues on
albumin were modified. In-vivo only four lysine residues were
identified as being modified in patient's plasma (Lys190,
Lys195, Lys432, and Lys541) [61]. These haptens were shown
to stimulate T-cells from hypersensitive patients and are the
likely trigger of the immune system. Certainly, the longer the
patient receives treatment the more likely it is that sensitisation
will develop. Flucloxacillin modifies the same lysine residues on
albumin as piperacillin; a reduction in piperacillin binding and the
piperacillin–albumin conjugate-specific T-cell response was seen
when flucloxacillin competed for binding sites. Potentially this
means that co-administering a competitor for binding sites could
prevent sensitisation in the first instance or even reduce the risk of
hypersensitivity in a patient with known sensitivity. We are now
undertaking a prospective study designed to elucidate further
the aetiology and risk factors for the development of drug
hypersensitivity.
We found skin testing to have a low sensitivity with only
14% of patients hypersensitive to piperacillin having a positive
intradermal test [61]. However, our retrospective studies found
positive in-vitro T-cell responses in patients hypersensitive to
sulfamethoxazole [60,62], piperacillin [61,63], meropenem and
aztreonam (unpublished data). This demonstrates that for the
non-immediate reactions that are commonly seen T-cells are
involved in the pathogenesis. The persistence of memory T-cells is
potentially life long, certainly they have been found to be present
with high numbers several years after the last exposure [63,64]. In
our studies positive piperacillin-specific lymphocyte responses
have been seen up to 12 years after the original reaction in the
absence of antigen. This suggests that piperacillin hypersensitive
Fig. 6. A) Rash. B) Skin biopsy showing an interface dermatitis reaction associated with vacuolar degeneration of the epidermal basal layer and numerous
individually necrotic keratinocytes. There is mild spongiosis and superficial dermal perivascular dermatitis reaction, which is mainly lymphocytic in character but
includes a few neutrophils. Immunostains confirm the lymphocytic infiltrate as being almost entirely T-cell in character, with a CD3+, CD45RO + phenotype. Both
CD4+ and CD8+ subsets are present.
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caution. Fortunately the T-cell responses in patients with CF are
highly drug-specific; T-cell clones are stimulated with the chemical
entity the patient was exposed to at the time of the reaction, but not
closely related drugs or other drugs commonly used in patients
with CF (Unpublished data). This is in keeping with the limited
cross-reactivity seen clinically.
Whilst alternative regimens can be devised for most patients
there are some multiple allergic patients for whom all options
have been exhausted. In this difficult group desensitization
represents the safest method of reintroducing the drug to the
patient. Desensitization results in a temporary state of immune
tolerance to the offending drug by gradual increasing a suboptimal
dose prior to the full therapeutic dose. In Leeds desensitization is
performed using a standard 7-step rapid intravenous protocol on a
normal medical ward [65]. Whilst desensitization is an established
procedure in patients with immediate reactions [66,67] there is
limited evidence to support desensitization in non-immediate
reactions [68,69]. We reviewed 275 desensitization procedures
in 42 patients with a range of non-immediate reactions to six
commonly used antibiotics [65]. The same desensitization
regimen was used as in that for immediate reactions. Individual
patient success ranged from 55% with tazocin through to 88%
with tobramycin. In the 25 patients who failed desensitization
the reactions were milder than their original reactions and the
majority occurred within 48 h of starting treatment. Prophy-
lactic anti-histamines and steroids did not reduce the risk of
reaction. At present little is known about the mechanisms of
desensitization for non-immediate reactions. Further studies
are on-going in which patients with confirmed hypersensitivity
are being desensitized to assess immune modulation.
2.4.7. Other complications of intravenous antibiotics
The frequent use of antibiotics can be associated with a host of
complications, many of which go unreported. One such example
is oral and genital candidiasis which although a commonproblem among patients with CF is often dealt with privately
and not conveyed to medical professionals. The long term use
of high dose antibiotics, steroids, oral contraception, urinary
incontinence and CF related diabetes make patients with CF
particularly susceptible to such infections. A questionnaire
based survey of 101 consecutive inpatients and outpatients
reported symptoms of either oral and or genital Candida in
70% of cases with a significant number of individuals finding
their condition distressing [70].
Antibiotic disruption of the intestinal microbiota may also
cause susceptibility to Clostridium difficile a spore-forming
Gram-positive bacillus. The prevalence of C. difficile is an
emerging problem especially in those patients undergoing
transplantation. While some patient may remain asymptomatic,
others can develop life threatening colitis [71]. The composition of
commensal gut flora also has important and specific metabolic and
protective functions. For example Oxalobacter formigenes (OF)
is a Gram-negative, anaerobic bacterium whose main carbon
and energy sources are derived from oxalate metabolism [72].
Unfortunately OF is sensitive to many commonly used antibiotics
and its absence from the gut is associated with a predisposition to
the development of calcium oxalate renal stones.
2.4.8. Drug delivery
The route of drug administration can be responsible for a
host of complications. Examples include the bacterial and
fungal contamination of nebuliser and venous access devices
the latter being responsible for 80% of significant blood stream
infections [73–75]. Venous access devices are also responsible
for an increasing prevalence of venous thrombosis and this can
lead to significant pulmonary embolus (Fig. 7) [76].
2.4.9. Antibiotics and microbial resistance
Over the past decade long term, low dose macrolide antibiotics
have been shown to be an effective adjunct in the treatment of CF
lung disease. Their use has been supported by several high quality
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ment was beneficial and safe [77–79]. There is however growing
evidence that clinicians should perhaps take a more selective
approach to prescribing these agents. The prevalence of
Staphylococcus aureus and Haemophilus influenzaemacrolide
resistance has increased and recent data suggests that these
resistant genes are transferrable between bacteria [80,81].
The long term use of macrolides may predispose patients to
colonisation by non-tuberculous mycobacteria (NTM) especially
M. abscessus. In the mouse model, azithromycin appears to
inhibit intracellular killing of mycobacteria within macrophages
and resulted in chronic infection with NTM [82]. The increased
prevalence of NTM is of significant worry as colonisation/
infection can result in increased treatment burden and premature
decline in health status. In Leeds the number of patients culturing
NTM has remained relatively stable since 2009 although the
prevalence of M. abscessus appears to be increasing (Fig. 8). It
remains unclear how long we should prescribe a macrolide for.
Many units continue life-long treatment or until side effects
develop. However this is not supported by clinical trial data
which have lasted no more than 1.5 year and where the
maximum level of efficacy appears to occur at six months and
declines to almost zero at 1.5 year. Long term trials are needed
to address these issues and to ensure real long term benefit.
Multiple antibiotic-resistant P. aeruginosa is now also fre-
quently encountered in clinical practice and its acquisition is also
strongly associated with antibiotic use [83]. Whilst resistant
P. aeruginosa does not appear to lead to increased respiratory
decline other resistant organisms, such as Methicillin-resistant
S. aureus (MRSA), have been demonstrated to lead to increased
mortality. Dasenbrook and colleagues have shown both increased
mortality and a more rapid decline in lung function in patients
chronically colonised by MRSA [84,85]. If MRSA is transientFig. 7. Large pulmonary embolus within the right lower lobe pulmonary artery
extending to upper lobe pulmonary artery. Associated with thrombus formation
at the tip of a P.A.S. port line.then the relative risk returns to baseline, stressing the importance of
early identification and prompt eradication. It has been speculated
that patients with MRSA colonisation may have been worse at
baseline with more frequent antibiotics and hospital visits [86]. Of
concern is data suggesting that many strains identified in patients
with CF are not only community acquired but also can be very
aggressive with expression of Panton–Valentine leukocidin (PVL)
toxin [87,88].
It is not just bacterial resistance that is an increasing problem
in CF; recently it has been reported that Aspergillus fumigatus
resistance to itraconazole occurs in 8% of isolates from patients
with CF [89]. This resistance was strongly related to previous
exposure and many isolates were also resistant to voriconazole
and posaconazole. Unfortunately resistance does lead to treat-
ment failure in patients [90]. It remains unclear when anti-fungal
medication should be prescribed in patients; this is especially the
case when A. fumigatus is cultured from over half of patients with
CF [91]. In ABPA, which occurs in 15% of patients, there have
been no randomised controlled trials of the role of anti-fungal
medication [92]. It is essential we characterise patients better and
use anti-fungal medication appropriately given the risks of
resistance as well as significant side effects such as liver toxicity.2.5. Future perspectives
Cystic fibrosis remains a very complicated multisystem disease.
Despite optimism of potentially effective new treatments such as
gene therapy and drug modulators, irreversible organ damage is
likely to remain a long term challenge. Conventional therapy
includes complex drug regimens aimed at protecting the lungs
from recurrent pulmonary infections, airway inflammation and
permanent lung damage. Unfortunately drug complications and
side effects remain relatively common and a minority of patients
are being denied transplantation because of multiple drug allergy,
renal failure, liver disease and osteoporosis. Even those accepted
will be affected by today's treatment. Whatever the future holds,
adult CF physicians will need to be both specialists and generalists
if they are to address current and likely future challenges.
Despite using intravenous antibiotics for decades, some obvious
questions remain unanswered. How long should the duration of
treatment be? What is the best dose regimen? Should treatment be
elective or as required? Is treatment aimed at intrapulmonaryFig. 8. Annual prevalence of NTM among adult and paediatric patients
attending the Leeds unit.
Fig. 9. A cartoon drawn by a Leeds patient with CF expressing his view of antibiotics.
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sition? Is combination therapy really necessary? These important
questions need to be answered through well-designed appropri-
ately powered multicentre trials yielding results that impact on
the effectiveness of treatment and on the risk of serious com-
plications such as drug hypersensitivity, renal failure and bacterial
resistance. With an ageing population more emphasis needs to
be placed on balancing the relative risk of bacterial resistance,
potential synergy, ease of use, cost and limiting drug induced
complications (Fig. 9).
Key to future success is reducing patient treatment burden
while improving adherence to conventional therapy. This is
especially the case in vulnerable adolescents who often have
accelerated pulmonary decline [93]. On average adults with CF
spend almost 2 h per day taking their treatment and in some
cases, regimens are so onerous that they are incompatible with
normal life, making it increasingly difficult for patients to meet
the expectations of clinicians [94]. The psychological conse-
quences of living with CF are also significant with over 20% of
patients suffering from anxiety and 10% from symptoms of
depression [95,96]. The combination of low mood and poor
adherence can result in individuals failing to engage with
clinical teams, resulting in a worse quality of life and a poorer
clinical outcome [97,98]. Clinical teams responsible for CF
care must ensure that each patient is empowered and has
appropriate education as well as a clear personalised manage-
ment plan. This has the potential to improve health, reduce
exacerbation rates and the need for intravenous antibiotics.Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2013.04.014.
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